Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.43 |
| ▸ | NPY4R | P50391 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 3/20 | 0.39 |
| ▸ | CCND1 | P24385 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3649822 | 0.84 | NOTUM (0.66) | NOTUMTSHRRAB9AL3MBTL1GAA | |
| SCHEMBL29370778 | 0.84 | NOTUM (0.66) | NOTUMTSHRRAB9AL3MBTL1GAA | |
| Hydrochloric Acid SCHEMBL28144485 | 0.82 | NOTUM (0.63) | NOTUMTSHRRAB9AL3MBTL1GAA | |
| Hydrochloric Acid SCHEMBL16237239 | 0.82 | NOTUM (0.63) | NOTUMTSHRRAB9AL3MBTL1GAA | |
| SCHEMBL23902687 | 0.81 | NOTUM (0.58) | NOTUMTSHRRAB9AL3MBTL1GAA | |
| Hydrochloric Acid SCHEMBL28843911 | 0.81 | NOTUM (0.61) | NOTUMTSHRRAB9AL3MBTL1GAA | |
| SCHEMBL15702556 | 0.80 | NOTUM (0.66) | NOTUMTSHRRAB9AL3MBTL1GAA | |
| SCHEMBL1151123 | 0.79 | NOTUM (0.70) | NOTUMTSHRRAB9AL3MBTL1GAA | |
| SCHEMBL10477477 | 0.79 | NOTUM (0.70) | NOTUMTSHRRAB9AL3MBTL1GAA | |
| SCHEMBL5354348 | 0.78 | NOTUM (0.68) | NOTUMTSHRRAB9AL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1011670-A4 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | LILLY CO ELI (US) | 2004-10-27 | — | — | EP | claimed |
| JP-2003525901-A | — | — | 2003-09-02 | — | — | JP | claimed |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY | 2003-06-26 | — | — | US | claimed |
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | CONCORD (HK) INTERNATIONAL EDUCATION LIMITED (HK) | 2003-05-08 | — | — | US | claimed |
| EP-1265607-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001066110-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-09-13 | — | — | WO | claimed |
| WO-2001066111-A1 | COMPOSITIONS CONTAINING POTENTIAL SPLA2 INHIBITORS FOR THE TREATMENT OF PAIN | ELI LILLY AND COMPANY (US) | 2001-09-13 | — | — | WO | claimed |
| WO-2001055108-A2 | USE OF SPL A2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION | ELI LILLY AND COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| EP-1011670-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 2000-06-28 | — | — | EP | claimed |
| EP-1007056-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 2000-06-14 | — | — | EP | claimed |
| WO-1999016453-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | claimed |
| EP-0772592-A4 | 1H-INDOLE-1-FUNCTIONAL sPLA 2? INHIBITORS | LILLY CO ELI (US) | 1998-07-08 | — | — | EP | claimed |
| EP-0772592-A1 | 1H-INDOLE-1-FUNCTIONAL sPLA 2? INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | claimed |
| WO-1996003376-A1 | 1H-INDOLE-1-FUNCTIONAL sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | claimed |
| US-8039486-B2 | Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1638568-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-0772592-A1 | 1H-INDOLE-1-FUNCTIONAL sPLA 2? INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003376-A1 | 1H-INDOLE-1-FUNCTIONAL sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |
| WO-1996003376-A1 | 1H-INDOLE-1-FUNCTIONAL sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | IDO2, SPINT2, IDO1 | NOTUM 1158/4885TSHR 4056/4885RAB9A 4212/4885 |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | TPP2, PLAAT2, PLAA | NOTUM 398/4885TSHR 708/4885RAB9A 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.